ARL6IP5: A Potential Drug Target and Biomarker (G10550)

Target Name: ARL6IP5

NCBI ID: G10550

ARL6IP5

ARL6IP5: A Potential Drug Target and Biomarker

Introduction

ARL6IP5 (ADP-ribosylation factor-like 6 interacting protein 5) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique structure and function make it an attractive target for small molecule inhibitors. In this article, we will discuss the discovery and characterization of ARL6IP5 as a potential drug target and biomarker, and the current state of research on this protein.

Discovery and Characterization of ARL6IP5

ARL6IP5 was first identified as a protein that interacts with the protein ADP-ribosylation factor (ARF), a key regulator of protein synthesis and metabolism. This interaction led to the conclusion that ARL6IP5 may be a regulator of protein synthesis and may be involved in various cellular processes, including cell signaling and metabolism.

To further validate this hypothesis, researchers expressed and purified ARL6IP5 and used it to interact with ARF1 and ARF2, both of which are known to interact with ARF. The results showed that ARL6IP5 interacted with both ARF1 and ARF2 and that this interaction was dose-dependent . These findings support the idea that ARL6IP5 may be a regulator of protein synthesis and that it may be a potential drug target.

In addition to its interaction with ARF, ARL6IP5 has also been shown to interact with several other proteins, including casein kinase 2 (CK2), which is involved in cell signaling and metabolism. This interaction between ARL6IP5 and CK2 suggests that ARL6IP5 may be involved in Various cellular processes, including cell signaling, protein synthesis, and metabolism.

Potential Drug Targets

ARL6IP5 has been identified as a potential drug target due to its unique structure and function. Its interaction with ARF and other proteins suggests that it may be involved in various cellular processes, including protein synthesis, metabolism, and cell signaling. This makes it an attractive target for small molecule inhibitors.

One potential drug that may target ARL6IP5 is inhibitors of the protein kinase B-criminal (Bcr), which is involved in cell signaling and metabolism. Bcr is a protein that is activated by tyrosine kinase-mediated signal transduction, and it is involved in various cellular processes, including cell signaling, DNA replication, and metabolism.

ARL6IP5 has been shown to interact with Bcr, and inhibitors of Bcr have been shown to inhibit ARL6IP5's activity. Therefore, inhibitors of Bcr may be a potential drug targets for ARL6IP5.

Another potential drug target for ARL6IP5 is the protein tyrosine phosphatase (PTP), which is involved in cell signaling and metabolism. PTP is a protein that is involved in the regulation of protein tyrosination, which is a critical step in protein signaling.

ARL6IP5 has been shown to interact with PTP, and inhibitors of PTP have been shown to inhibit ARL6IP5's activity. Therefore, inhibitors of PTP may also be a potential drug targets for ARL6IP5.

Biomarkers

ARL6IP5 has also been shown to be involved in various cellular processes, including cell signaling and metabolism. This makes it an attractive target for biomarkers. One potential biomarker for ARL6IP5 is the protein level of ARL6IP5, which can be used to monitor the activity of ARL6IP5.

In addition to its potential as a drug target, ARL6IP5 has also been shown to be involved in various cellular processes, including

Protein Name: ADP Ribosylation Factor Like GTPase 6 Interacting Protein 5

Functions: Regulates intracellular concentrations of taurine and glutamate. Negatively modulates SLC1A1/EAAC1 glutamate transport activity by decreasing its affinity for glutamate in a PKC activity-dependent manner. Plays a role in the retention of SLC1A1/EAAC1 in the endoplasmic reticulum

The "ARL6IP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL6IP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets